Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Investigating Mechanisms of Alport Syndrome

EF 2022-23

Résumé
Alport syndrome (AS) is a rare monogenic disorder and an understated cause of chronic kidney disease. Symptoms include vision loss, hearing loss, and kidney disease manifesting as hematuria, albuminuria, and organ failure. AS results from variants in COL4A3, COL4A4, or COL4A5, which encodes the a3, a4, a5 chains of type IV collagen (a3a4a5(IV)) found in the kidney's glomerular basement membrane (GBM). The most severe forms of AS are caused by mutations in one of these genes, leading to persistence of an immature type IV collagen network (a1a1a2(IV)). While the mechanisms governing AS remain relatively unknown, the Barua lab has identified upregulation of an enzyme involved in post translational modification (PTM) of type IV collagen in Col4a3 knockout (KO) mice compared to control mice. I hypothesize the upregulation of this enzyme is involved in stabilizing the GBM to confer biomechanical properties to a1a1a2(IV) that mimics a3a4a5(IV) in Col4a3 KO mice. We have constructed a transgenic mouse by DNA pronuclear injection to overexpress the enzyme. My aims are to characterize (1) 3 transgenic mouse founders and; (2) Col4A3 KO mice that are crossed with each transgenic mouse line. Copy number and genomic location of transgene integration will be determined, with allele-specific assays designed to differentiate between the 3 transgenic mice founder lines. Overexpression will be evaluated with digital droplet PCR and western blot of kidney tissue. Phenotyping of all mice will be performed by measuring serum creatinine, urine albumin:creatinine ratio, and electron microscopy on kidney tissue. I predict that enzyme overexpression in Col4a3 KO mice will attenuate kidney disease in AS. If the hypothesis is supported, this enzyme may serve as a future therapeutic target.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486167
Name
Ricardo Samantha A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating Mechanisms of Alport Syndrome
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alport Syndrome; Dna Pronuclear Injection; Genetic Disorders; Genetics; Glomerular Basement Membrane; Kidney Disease; Kidney Failure; Post-Translational Modifications; Transgenesis; Type Iv Collagen
Abstract
Alport syndrome (AS) is a rare monogenic disorder and an understated cause of chronic kidney disease. Symptoms include vision loss, hearing loss, and kidney disease manifesting as hematuria, albuminuria, and organ failure. AS results from variants in COL4A3, COL4A4, or COL4A5, which encodes the a3, a4, a5 chains of type IV collagen (a3a4a5(IV)) found in the kidney's glomerular basement membrane (GBM). The most severe forms of AS are caused by mutations in one of these genes, leading to persistence of an immature type IV collagen network (a1a1a2(IV)). While the mechanisms governing AS remain relatively unknown, the Barua lab has identified upregulation of an enzyme involved in post translational modification (PTM) of type IV collagen in Col4a3 knockout (KO) mice compared to control mice. I hypothesize the upregulation of this enzyme is involved in stabilizing the GBM to confer biomechanical properties to a1a1a2(IV) that mimics a3a4a5(IV) in Col4a3 KO mice. We have constructed a transgenic mouse by DNA pronuclear injection to overexpress the enzyme. My aims are to characterize (1) 3 transgenic mouse founders and; (2) Col4A3 KO mice that are crossed with each transgenic mouse line. Copy number and genomic location of transgene integration will be determined, with allele-specific assays designed to differentiate between the 3 transgenic mice founder lines. Overexpression will be evaluated with digital droplet PCR and western blot of kidney tissue. Phenotyping of all mice will be performed by measuring serum creatinine, urine albumin:creatinine ratio, and electron microscopy on kidney tissue. I predict that enzyme overexpression in Col4a3 KO mice will attenuate kidney disease in AS. If the hypothesis is supported, this enzyme may serve as a future therapeutic target.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ricardo, Samantha A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~